Hyperinflation refers to the lung’s increase in size due to the trapped air that has caused them to expand. The BREATHE-3 trial uses self-expanding nitinol airway scaffolds that are placed ...
Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases. Persistent, intensely itchy rashes in older adults are often written off as eczema or ...
NORTH PHILADELPHIA (WPVI) -- There's a potential new treatment for severe emphysema, and Philadelphia is a key test site for this small device with big potential to improve lives. In COPD (Chronic ...
A baby girl defied all the odds to survive after being born so early her foot was the size of her dad’s fingertip and her eyes were sealed shut. Brave tot Jemima James, now aged one, was born weighing ...
A gene therapy injected into patients’ brains slowed progression of the disease by 75 percent, preliminary findings reported. By Dana G. Smith Preliminary results from a small clinical trial to treat ...
DEAR DR. ROACH: I am a 73-year-old woman who is in otherwise good health, but I was diagnosed with bullous pemphigoid, a rare autoimmune disease, in January 2022. I have been treated by three ...
Visually assessed pulmonary emphysema independently predicted modestly elevated all-cause mortality risk over 25 years of follow-up in patients with a history of smoking. After controlling for other ...
Bullous pemphigoid (BP) is an autoimmune disorder that mainly affects older adults. The condition causes your immune system to attack proteins that hold the layers of your skin together. This damages ...
Regeneron and Sanofi Announce FDA Approval of Dupixent for Treatment of Bullous Pemphigoid in Adults
The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults with bullous pemphigoid (BP), a chronic and debilitating skin disease primarily affecting the elderly ...
More patients treated with dupilumab experienced sustained disease remission and itch reduction at week 36 compared with those who received placebo. The Food and Drug Administration (FDA) has approved ...
The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results